NCT06726161View on ClinicalTrials.gov

Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ Unresectable HCC

PHASE1RecruitingINTERVENTIONAL

Enrollment

70

Participants

Timeline

Start Date

November 15, 2024

Primary Completion Date

March 31, 2029

Study Completion Date

January 31, 2031

Conditions

HCC

Interventions

DIAGNOSTIC_TEST

RYZ811

Ga-68

DRUG

RYZ801

Ac-225

Trial Locations (2)

35233

RECRUITING

Research Facility, Birmingham

49503

RECRUITING

Research Facility, Grand Rapids

All Listed Sponsors

lead

RayzeBio, Inc.

INDUSTRY